As published in their initiating research note from Guggenheim on October 19, 2022, Reata Pharmaceuticals Inc. [RETA] has been a Buy and the price target has been revised to $75. This represents a 32.73% premium over Thursday’s closing price. As of December 09, 2021, SVB Leerink has decreased its “an Outperform” rating to a “Mkt perform” for RETA. Earlier on December 09, 2021, Robert W. Baird downgraded its rating. Their new recommendation was “a Neutral” for RETA stock which previously was a “an Outperform”.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Analyzing RETA Stock Performance
On Thursday, Reata Pharmaceuticals Inc. [NASDAQ: RETA] rose 11.05% to $50.45. The stock’s lowest price that day was $45.61, but it reached a high of $50.47 in the same session. During the last five days, there has been a surge of approximately 18.71%. Over the course of the year, Reata Pharmaceuticals Inc. shares have jumped approximately 32.80%. Shares of the company reached a 52-week high of $51.98 on 02/08/23 and a 52-week low of $33.85 on 01/06/23. A 50-day SMA is recorded $40.46, while a 200-day SMA reached $32.73. Nevertheless, trading volume fell to 2.11 million shares from 1.15 million shares the previous day.
Support And Resistance Levels for Reata Pharmaceuticals Inc. (RETA)
According to the 24-hour chart, there is a support level at 47.22, which, if violated, would cause prices to drop to 43.98. In the upper region, resistance lies at 52.08. The next price resistance is at 53.70. RSI (Relative Strength Index) is 61.24 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.08, which suggests the price will decrease in the coming days. Percent R is at 10.79%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Reata Pharmaceuticals Inc. subject to short interest?
Stocks of Reata Pharmaceuticals Inc. saw a sharp rise in short interest on Jan 12, 2023 jumping by 0.82 million shares to 8.14 million. Data from Yahoo Finance shows that the short interest on Dec 14, 2022 was 7.32 million shares. A jump of 10.07% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 16.51 of the overall float, the days-to-cover ratio (short ratio) jumped to 16.51.
Which companies own the most shares of Reata Pharmaceuticals Inc. (RETA)?
According to CPMG, Inc. filings, the company currently owns 2,896,901 shares, which is about 9.13% of the total RETA shares outstanding. With the completion of the buy transaction, The Vanguard Group, Inc.’s stake is now worth $114,279,495. First Light Asset Management LLC acquire a 95.50% interest valued at $89.37 million while BlackRock Fund Advisors purchased a 173,985 stake. A total of 897,481 shares of Reata Pharmaceuticals Inc. were bought by Fred Alger Management LLC during the quarter, and -64,384 were sold by Wellington Management Co. LLP. In its current portfolio, DWS Investment GmbH holds 1,467,498 shares valued at $63.59 million.
In terms of Reata Pharmaceuticals Inc. share price expectations, FactSet research, analysts set an average price target of $62.40 in the next 12 months, up nearly 25.47% from the previous closing price of $45.43. Analysts anticipate Reata Pharmaceuticals Inc. stock to reach $115.00 by 2023, with the lowest price target being $35.00. In spite of this, 10 analysts ranked Reata Pharmaceuticals Inc. stock as an Overweight at the end of 2023. On May 24, 2021, Goldman assigned a price target of “a Buy” to the stock and initiated coverage with a $236.